Long-term GLP-1 maintenance is about consistent dosing, ongoing provider access, and predictable cost — not about microdosing gimmicks or promotional pricing that shifts once you're past the introductory period.
Luma Health's flat pricing ($197/month semaglutide, $297/month tirzepatide) doesn't change between your starting dose and your maintenance dose, which matters most for the months and years of maintenance that follow initial weight loss.
Most of the attention in GLP-1 marketing goes to the initial weight-loss phase, but maintenance — the months and years after you've reached your goal — is where a program's actual structure matters most. Here's what a good long-term maintenance approach looks like.
Why Maintenance Is a Different Phase
Once you've reached your target weight, the clinical goal shifts from active weight loss to sustaining it, which for most patients means continuing GLP-1 treatment at a stable maintenance dose rather than stopping. Research on stopping semaglutide shows meaningful weight regain within a year for most patients who discontinue — underscoring that obesity is treated as a chronic condition requiring ongoing management, similar to blood pressure or cholesterol medication, not a short course that ends once a goal is hit.
What Should (and Shouldn't) Change at Maintenance
Your dose may be adjusted downward once you're at a stable weight, depending on how you're tolerating your current dose and your provider's clinical judgment — this is a legitimate, provider-guided decision, not something to self-manage. What shouldn't change is the fundamentals: continued access to your provider for questions, consistent medication supply, and monitoring for any long-term considerations relevant to your health profile.
Some programs advertise low introductory pricing tied to starting doses, with costs rising as you reach the higher maintenance doses most patients settle into long-term. If a program's advertised price is meaningfully lower than what you'll actually pay once you're at maintenance, that's worth factoring into your real long-term cost comparison — not just your first month's bill.
A Note on Microdosing for Maintenance
Some programs market "microdosing" — using lower-than-standard doses — as a maintenance strategy, sometimes framed as reducing side effects or cost. This isn't a standard, extensively studied dosing approach backed by the same clinical trial data as FDA-labeled dosing schedules, and any dose below the studied range should be a provider's individualized clinical decision based on your specific response, not a default marketing strategy applied broadly.
What Actually Matters for Long-Term Maintenance
Over months and years of maintenance, the things that matter most are: predictable pricing that doesn't surprise you once you've settled into a stable dose, consistent access to your provider without having to re-justify your treatment repeatedly, and a straightforward refill process that doesn't require renegotiating your program terms every few months.
What to Prioritize for Maintenance
- What you'll actually pay at your expected maintenance dose, not just the starter price
- Whether ongoing provider access is included or requires additional fees
- How refills and dose adjustments work once you're stable
- Flat pricing that doesn't rise as your dose stabilizes higher
- Ongoing provider check-ins, not a one-time prescription
- Clear guidance on refill timing to avoid a treatment gap
Built for the long run,
not just month one
Compounded semaglutide at $197/month or tirzepatide at $297/month — the same price at your starting dose and your maintenance dose.
Get Started → Or start your free health assessmentFrequently Asked Questions
Not necessarily forever, but most patients continue at a maintenance dose, since stopping is associated with meaningful weight regain for most people within a year. This is a decision to make with your provider based on your individual situation.
Possibly, depending on your tolerance and your provider's clinical judgment. Some patients transition to a lower maintenance dose; others continue at their existing dose. This should be a provider-guided decision.
Using doses below the studied clinical range isn't backed by the same extensive trial data as FDA-labeled dosing, and should be an individualized provider decision based on your specific response, not a default strategy.
Some providers price by dose tier, meaning cost rises as you move from a starting dose to a higher maintenance dose. Confirm whether a program's advertised price reflects your expected long-term dose, not just the starting price.
Predictable pricing, ongoing provider access for questions and adjustments, and a straightforward refill process — without requiring you to renegotiate terms repeatedly.
No. Luma Health's $197/month semaglutide and $297/month tirzepatide are flat regardless of dose, including maintenance doses.
References
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed 35441470
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed 35658024
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database